Sustainability
Guided by our mission” Contributing to Better Health All Over the World” we actively advance sustainability strategies, address stakeholder priorities, and pursue balanced growth across economic, social, and environmental dimensions.
Our Strategy and Approach
Grounded in our core mission to Contribute to Better Health All Over the World, we integrate sustainability into our pharmaceutical expertise by aligning with stakeholder expectations and global standards. Since 2022, we have advanced our efforts through a dedicated Sustainability Committee focused on 5 strategic pillars linked to the UN SDGs.
By setting clear goals and embedding sustainable practices across our operations, we aim to enhance our competitiveness while delivering long-term value to society, the environment, and the broader healthcare ecosystem.
Message from the Chairman and CEO
Since Bora was founded in 2007, our journey has required patience and sustained investment. Contract pharmaceutical manufacturing is not an industry where speed alone determines success. It requires the continuous accumulation of technical capabilities, regulatory credibility, customer trust, and the organizational capacity to effectively integrate new businesses following each acquisition.
In 2025, our multi-year investments began translating more concretely into operational capabilities. Our international CDMO footprint is now largely established, with manufacturing sites in Taiwan, the United States, and Canada each carrying a defined technical mandate. Group-wide quality management standards have also continued to strengthen and converge.
Commercially, new CDMO contract signings reached a record high during the year, while our specialty pharmaceutical business continued to gain market share in pediatric epilepsy. These achievements demonstrate growing international recognition of Bora’s dual-engine business model.
Access to medicine remains central to our long-term commitment. Through the continued supply of medicines for rare diseases, including VIGAFYDE®, Vigadrone and Deflazacort, as well as the Promise of Support® Program, we continue to support patients, caregivers and healthcare providers throughout the treatment journey.
We are also progressively expanding Scope 1 and Scope 2 greenhouse gas inventory coverage across the Group, while advancing SBTi alignment and Scope 3 preparation at our Canadian facility. Our focus is on establishing actionable milestones supported by effective implementation.
As regulatory expectations, technology cycles and supply-chain conditions continue to evolve, Bora will strengthen its governance and risk management frameworks and maintain timely, transparent communication with stakeholders. We remain committed to our pharmaceutical expertise and core mission, “Contributing to Better Health All Over the World,” as we advance toward becoming a top-ten global CDMO.
Bobby Sheng Group CEO & Chairman
Highlights of the Year
Environment
ISO 14064-1
The Group has implemented ISO 14064-1 since 2021 and completed third-party verification for three consecutive years.
Net-Zero
Commitment
Bora Group is committed to achieving net-zero emissions by 2050
Social
Promise of Support™
Specialized services for rare disease communities, ensuring comprehensive support for patients, caregivers, and healthcare providers throughout the treatment process
Sustainability Governance
Reports
Read our latest reports to see the progress we’re making in advancing sustainability across our business.
Our Ratings Overview
Morgan Stanley Capital International ESG Rating
Bora has been awarded an “A” rating by Morgan Stanley Capital International (MSCI) for its Environmental, Social and Governance (ESG) performance. The MSCI ESG Ratings assess a company’s resilience to long-term, industry-specific ESG risks and opportunities, and benchmark it against global peers.
EcoVadis Rating
Bora Group has been recognized as “Committed” by EcoVadis. The EcoVadis assessment covers 21 sustainability criteria across four categories: environment, labor & human rights, ethics, and sustainable procurement. The methodology is aligned with international standards such as the Global Reporting Initiative (GRI), United Nations Global Compact, and the International Labour Organization (ILO).
TWSE's Corporate Governance Evaluation Ranking
Bora has been ranked in the top 6–20% in the Taiwan Stock Exchange (TWSE) Corporate Governance Evaluation. This achievement highlights Bora’s dedication to robust governance and oversight. We have also been newly included in the “Corporate Governance 100 Index” and selected as a constituent of the Fubon Corporate Governance ETF (00692), reflecting the market’s recognition of our governance standards.
FTSE Russell Score
Bora has achieved an ESG rating of 3.5 out of 5 from FTSE Russell, meeting the qualification criteria for inclusion in the FTSE4Good Index Series.
The FTSE4Good Index is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices.
World Finance – Most Sustainable Company
Bora was recognized by World Finance as the Most Sustainable Company in the pharmaceutical industry, acknowledging the Company’s sustainability performance and long-term commitment to responsible pharmaceutical operations.
Canada’s Safest New Employer
Bora’s Mississauga site received the Bruce Power Award for Canada’s Safest New Employer at the 2025 Canada’s Safest Employers Awards.